GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Genomtec SA (WAR:GMT) » Definitions » Net Current Asset Value

Genomtec (WAR:GMT) Net Current Asset Value : zł0.48 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Genomtec Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Genomtec's net current asset value per share for the quarter that ended in Mar. 2025 was zł0.48.

The historical rank and industry rank for Genomtec's Net Current Asset Value or its related term are showing as below:

WAR:GMT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 14.21   Med: 36.71   Max: 253.33
Current: 14.25

During the past 7 years, the highest Price-to-Net-Current-Asset-Value Ratio of Genomtec was 253.33. The lowest was 14.21. And the median was 36.71.

WAR:GMT's Price-to-Net-Current-Asset-Value is ranked worse than
79.9% of 582 companies
in the Medical Devices & Instruments industry
Industry Median: 4.94 vs WAR:GMT: 14.25

Genomtec Net Current Asset Value Historical Data

The historical data trend for Genomtec's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomtec Net Current Asset Value Chart

Genomtec Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Current Asset Value
Get a 7-Day Free Trial 0.77 -0.15 -0.20 -0.08 -0.07

Genomtec Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.27 0.28 0.03 -0.07 0.48

Competitive Comparison of Genomtec's Net Current Asset Value

For the Medical Devices subindustry, Genomtec's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomtec's Price-to-Net-Current-Asset-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Genomtec's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Genomtec's Price-to-Net-Current-Asset-Value falls into.


;
;

Genomtec Net Current Asset Value Calculation

Genomtec's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2024 is calculated as

Net Current Asset Value Per Share(A: Dec. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(8.489-9.441-0-0)/13.343
=-0.07

Genomtec's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2025 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(15.874-8.73-0-0)/14.867
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genomtec  (WAR:GMT) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Genomtec Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Genomtec's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomtec Business Description

Traded in Other Exchanges
Address
ul. Stab?owicka 147, PORT Building 2, Wroclaw, POL, 54-066
Genomtec SA is an innovative technology company which works in the area of ?? molecular diagnostics. It is a manufacturer of mobile molecular analyzers. The device are designed to identify pathogens including viruses, bacteria, and fungi by amplifying and detecting specific DNA and RNA fragments.

Genomtec Headlines

No Headlines